Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels
{{output}}
Background: Burosumab, an antifibroblast growth factor 23 monoclonal antibody, improves rickets severity, symptoms and growth in children with X-linked hypophosphataemia (XLH) followed up to 64 weeks in clinical trials. Internati... ...
